Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Leuk Lymphoma. 2019 Jan 18;60(5):1261–1265. doi: 10.1080/10428194.2018.1519812

Table 1.

Patient Characteristics by Treatment Status

Overall* (n=43) R-CHOP + radiation (n=10) R-CHOP alone (n=16) R-CHOP with escalation (n=7) DA-R-EPOCH
(n=9)
Median Follow-up (mon) 35.8 46.6 42.7 97.4 13.8

Age at Dx
 median(range) 36 (14,60) 40.5 (19,60) 36 (23,52) 41 (21,44) 33 (14,51)

Gender Female – n(%)
22 (51.2) 2 (20) 11 (68.8) 5 (71.4) 3( 33.3)

Stage at Dx - n(%)
 III-IV 9 (20.9) 1(10) 3 (18.8) 4 (57.1) 1 (11.1)

LDH High**
29 (67.4) 8 (80) 12 (75) 5 (71.4) 3 (33.3)

ECOG PS – n(%)
 2–4 5 (11.6) 2 (20) 2 (12.5) 1 (14.3) 0

Age-adjusted IPI
 0 13 (30) 2 (20) 4 (25) 0 6 (66.7)
 1 18 (42) 5 (50) 7 (43.8) 4 (57.1) 2 (22.2)
 2 12 (28) 3 (30) 5 (31.2) 3 (42.9) 1 (11.1)
 3 0 0 0 0 0

Pericardial effusion – n(%)
17 (39.5) 3 (30) 8 (50) 1 (14.3) 4 (44.4)

Pleural effusion - n(%)
13 (30.2) 4 (40) 3 (18.8) 2 (28.6) 4 (44.4)

Bulky-n(%)
 >10cm 20 (46.5) 5 (50) 9 (56.3) 3 (42.9) 3 (33.3)

SVC syndrome-n(%)
9 (20.9) 3 (30) 4 (25) 1 (14.3) 1 (11.1)
*

One patient with RCHOP+HIDAC was not listed in the next following columns

**

LDH high = LDH above the upper limit of normal